Национальное Интернет Общество
специалистов по внутренним болезням


Latest trial results and best use of Mineralocorticoid receptor antagonists (MRAs) – Eplerenone

29 Мая 2017

The fifthprogram in cycle «Games of chess 3.0»

Over time mineralocorticoid receptorantagonists (MRAs)has been consideredin CHF as a drug to enhance the diuretic effect of thiazides and loopdiuretics, what can reduce the risk of hypokalemia. However, now MRAs regard as the main drug class for CHF treatment. 

Thus, during the lastten years the positions of eplerenone have significantly increased. In 2011results of the EMPHASIS-HF trial demonstrated that the addition of eplerenoneto standard therapy reduces overall and cardiovascular mortality, and rate ofhospitalization of patients with CHF NYHA-FCII and LVEF ≤35%. 

The subgroup analyses have not stopped for 6 years and continue to surprise us.New interesting data of additional studies will be discussed in the program in cycle «Games of chess 3.0» with participation of Faiez Zannad, MD, PhD, Professor of theDepartment of Therapy at the University of Lorraine (Nancy, France).

Speaker: Prof. Faiez Zannad (Nancy, France)
Moderator: Prof. Sergey R. Gilyarevsky (Moscow, Russian Federation) 

Broadcast schedule: 29 May 2017 19.00 - 20.00(Moscow time)

For Russian version, click here

This event is supported by Pfizer.